Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer.

"code availability the statistical code for our main analyses is available at https://github com/yuehanwanggitub/ipdanthracyclines git ."

"Competing interests The authors declare no competing interests."

"This work was supported by the Children Cancer Free Foundation (KiKa; grant 325 title: risk factors for female breast cancer after treatment for childhood and adolescent cancer: individual patient data analyses of an internationally pooled cohort) to C.M.R., F.E.v.L., L.C.M.K. (principal investigators). The CCSS and SJLIFE cohorts are supported by the National Cancer Institute (CA55727 to G.T.A. (principal investigator) and CA195547 to M.M.H. and K.K.N. (principal investigators)) as well as support to St. Jude Children’s Research Hospital also provided by the Cancer Center Support (CORE) grant (CA21765 to C.R. (principal investigator)) and the American Lebanese-Syrian Associated Charities (ALSAC). The NWTSG was supported by the National Cancer Institute (CA054498 to N.E.B. and W.L. (principal investigator)). The DCCSS-LATER is supported by the Dutch Cancer Society (DCOG2011-5027 to C.M.R., F.E.v.L. and W.T. (principal investigators) and UVA2012-5517 to C.M.R. and L.C.M.K. (principal investigators)). The FCCSS is funded by the Fondation ARC (PopHARC Grant to F.d.V. (principal investigator)), the Agence Nationale pour la Recherche Médicale (ANR, Hope-Epi Grant to F.d.V. (principal investigator)), and the Gustave Roussy Foundation (Pediatric Program ‘Guérir le Cancer de l’Enfant’ to F.d.V. (principal investigator)). The SCCSS has been supported by the Swiss Cancer League and the Swiss Cancer Research foundation (KFS-02783-02-2011, KLS-3412-02-2014, KFS-4157-02-2017, KLS/KFS-4825-01-2019, KFS-4722-02-2019, KFS-5027-02-2020, KFS-5302-02-2021 and KLS-5432-08-2021 to C.E.K. (principal investigator)), Kinderkrebs Schweiz (www.kinderkrebs-schweiz.ch) and Kinderkrebshilfe Schweiz (www.kinderkrebshilfe.ch). The Dutch Hodgkin Late Effects cohort has been supported by the Dutch Cancer Society (NKI 2010-4720 to F.E.v.L. (principal investigator))."